Journal
BIOMOLECULES
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biom12020165
Keywords
prostate cancer; enzyme inhibition
Categories
Ask authors/readers for more resources
In this study, twenty new compounds targeting CYP17A1 were synthesized and evaluated for their biological activity. One compound showed comparable potency and selectivity to existing drugs.
Twenty new compounds, targeting CYP17A1, were synthesized, based on our previous work on a benzimidazole scaffold, and their biological activity evaluated. Inhibition of CYP17A1 is an important modality in the treatment of prostate cancer, which remains the most abundant cancer type in men. The biological assessment included CYP17A1 hydroxylase and lyase inhibition, CYP3A4 and P450 oxidoreductase (POR) inhibition, as well as antiproliferative activity in PC3 prostate cancer cells. The most potent compounds were selected for further analyses including in silico modeling. This combined effort resulted in a compound (comp 2, IC50 1.2 mu M, in CYP17A1) with a potency comparable to abiraterone and selectivity towards the other targets tested. In addition, the data provided an understanding of the structure-activity relationship of this novel non-steroidal compound class.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available